| 2.03 -0.05 (-2.4%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.55 | 1-year : | 2.98 |
| Resists | First : | 2.19 | Second : | 2.55 |
| Pivot price | 1.98  |
|||
| Supports | First : | 1.83 | Second : | 1.61 |
| MAs | MA(5) : | 2.04 |
MA(20) : | 1.92 |
| MA(100) : | 2.11 |
MA(250) : | 1.77 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 75.7 |
D(3) : | 74.1 |
| RSI | RSI(14): 53.7 |
|||
| 52-week | High : | 4.46 | Low : | 1.02 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALLO ] has closed below upper band by 37.5%. Bollinger Bands are 33.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.09 - 2.1 | 2.1 - 2.11 |
| Low: | 1.97 - 1.99 | 1.99 - 2 |
| Close: | 2.01 - 2.03 | 2.03 - 2.05 |
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Mon, 17 Aug 2026
symbol__ Stock Quote Price and Forecast - CNN
Mon, 17 Aug 2026
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Mon, 17 Aug 2026
Citizens reiterates Allogene stock rating on trial progress - Investing.com
Fri, 14 Aug 2026
Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy - CRISPR Medicine News
Thu, 13 Aug 2026
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs - TradingView
Thu, 13 Aug 2026
Allogene Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 345 (M) |
| Shares Float | 271 (M) |
| Held by Insiders | 11 (%) |
| Held by Institutions | 62.7 (%) |
| Shares Short | 59,710 (K) |
| Shares Short P.Month | 48,040 (K) |
| EPS | -0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.13 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -52.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.39 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -109 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | -2.64 |
| PEG Ratio | 0 |
| Price to Book value | 1.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|